Permanent ~(125)I prostate brachytherapy for hormone-refractory prostate cancer
- VernacularTitle:~(125)I放射粒子植入治疗激素难治性前列腺癌
- Author:
Yi HUANG
;
Lulin MA
;
Junjie WANG
;
Al ET
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Radiosurgery
- From:
Chinese Journal of Urology
2001;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical significance of permanent 125 I prostate brachytherapy in patients with hormone refractory prostate cancer. Methods A total of 15 patients with hormone refractory prostate cancer underwent 3 dimensional conformal brachytherapy with transperineal ultrasound guide 125 I seeds prostate implantation. Of them 5 patients with bone metastases were treated by EBRT one month later. Results The mean number of 125 I seeds implanted was 56.The mean operation time was 70 min,and mean hospital stay was 5 d.All patients were followed up for 5 to 28 months with a mean of 11 months.5 cases had complete reaction;4, partial reaction;3,stable condition;and 3 developed progressive disease. PSA progression free survival rate was 80% (12/15).No severe complication occurred in all cases. Conclusions Brachytherapy with 125 I seeds implantation guided by transrectal ultrasound is a safe,minimally invasive and effective treatment with low morbidity for hormone refractory prostate cancer patients.
